Watch Scientific and Medical Equipment House Company for free: we tell you when fair value or trend changes.

Scientific and Medical Equipment House Company (4014) fair value: what the stock is really worth

As of Oct 28, 2026: fair value (intrinsic value) of Scientific and Medical Equipment House Company stock SAR 12.68, price SAR 26.16, upside -51.5%, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value 30%+ above price?No
Quality 50+?No
In an uptrend?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare · SA · ISIN SA15GGQ1UN19

Broad data Oct 27, 2026

Scientific and Medical Equipment House Company

4014 · SR

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 52% below what the stock costs today.

Low debt

Broad data

Quality 50/100

Expensive Growth (revenue 5y +6.1 %/yr in SAR)

Thin margins · 3.5% net margin (TTM)

Fair value 12.68 SAR · Strongly overvalued (−51.5%)

Negative free cash flow

Trails peers (4/13)

Narrow moat 30/100 · thin data

26 models, one by oneBear 9.46 SAR to bull 16.88 SAR Growth analysisrevenue history, year by year Quality 50/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Scientific and Medical Equipment House Company for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.

How to read this chart

56‑month range 24.47 SAR – 57.56 SAR · fair‑value band 9.46 SAR – 16.88 SAR · the 26.16 SAR price screens above the 12.68 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.

Follow Scientific and Medical Equipment House in your weekly email

Every Wednesday you see whether Scientific and Medical Equipment House is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Scientific and Medical Equipment House Company provides technological solutions and services for healthcare and catering projects in the Kingdom of Saudi Arabia.

Show moreShow less

It operates through operation and Maintenance, Medical Equipment Sales and Post-Sale Maintenance Services Revenue, Construction, Meat and Food, and Medicine and Medical Supplies segments.

It engages in the supply of medical and nonmedical staff; general contracting of buildings, roads, bridges, dams, electrical, electronic, and mechanical works; operation of restaurants and hospitals; maintenance and operation of industrial, water, and sewage works; maintenance of scientific and medical equipment; sale of safety equipment; installation and maintenance of firefighting and fire alarm equipment, lighting systems and equipment, cooling, air conditioning, electric, gas, and oil heating systems; filling and maintenance of fire extinguishers; sale, installation, and maintenance of security surveillance cameras, security detectors, inspection, and burglar alarm devices; and manufacture of radiological equipment, tubes, and devices.

It is also involved in the repair and maintenance of radiological, electronic, medical and therapeutic equipment; export, wholesale, and retail trade in medical, electronical, electrical, and mechanical equipment and devices, laundries, incinerator equipment, and pumps; manufacture of pacemakers and ECG devices; installation and extension of television, satellite, computer, telecommunications networks, Installation and maintenance of fire alarm, security systems and equipment, and electrical and communication wires; and wholesale of food and drinks.

In addition, it provides catering and private civil security guard services, cleaning services, building maintenance and land freight services, and refrigerated food warehouse services, as well as meat, frozen vegetables, and dry food.

The company was incorporated in 1979 and is based in Riyadh, the Kingdom of Saudi Arabia.

Stock analysis

Scientific and Medical Equipment House Company (4014) currently trades at 26.16 SAR, while our model-based Fair Value estimate is 12.68 SAR, 51.5% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of 18.25 SAR per share, and 1 of the 17 models we run sit above the 26.16 SAR price.

Bear case: the Earnings-Based group reads lowest at 6.04 SAR, and 16 of the 17 models stay below the price. Data coverage for this calculation is high.

Scenario range: 9.46 SAR (bear) to 16.88 SAR (bull), the price of 26.16 SAR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Scientific and Medical Equipment House Company reported revenue of 877M SAR in FY2025 versus 699M SAR in FY2021, a compound +5.8%/yr. Reported net income was 28.4M SAR in FY2025, compounding −22.2%/yr from FY2021.

Key figures

Market cap 782M SAR (≈ $208M) Micro · P/E ratio 28.4 · P/S ratio 0.99 · EPS (TTM) 0.9200 SAR · Dividend yield 3.8% · Net margin 3.5% · Return on equity 5.0% · Return on assets (EBIT) 6.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −42% fair-value upside, at −52%, 4014 screens richer than that median.

Fair Value models

Bear 9.46 SAR Fair Value 12.68 SAR Bull 16.88 SAR

Price 26.16 SAR · Upside -51.5%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.7612 SAR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

Owner Earnings 8.02 SAR 11.08 SAR 14.98 SAR 77

Residual Income 12.32 SAR 12.44 SAR 13.00 SAR 76

EPV 7.11 SAR 7.95 SAR 8.64 SAR 74

All 17 models by family

DCF Models

Owner Earnings 8.02 SAR 11.08 SAR 14.98 SAR 77

Earnings-Based

Graham-Dodd 6.44 SAR 19.68 SAR 26.12 SAR 65

Lynch FV 4.23 SAR 6.04 SAR 7.85 SAR 61

PEG = 1.0 4.23 SAR 6.04 SAR 7.85 SAR 57

EPV 7.11 SAR 7.95 SAR 8.64 SAR 74

Dividend Discount

Gordon GGM 7.33 SAR 12.68 SAR 16.88 SAR 68

DDM Multi-Stage 7.33 SAR 11.10 SAR 13.60 SAR 67

Multiples

P/E Multiple 15.62 SAR 20.83 SAR 26.03 SAR 63

P/S Multiple 12.07 SAR 16.09 SAR 20.12 SAR 58

P/B Multiple 57.09 SAR 76.12 SAR 95.15 SAR 55

EV/EBIT 11.40 SAR 17.10 SAR 22.79 SAR 65

EV/EBITDA 14.46 SAR 21.18 SAR 27.90 SAR 67

EV/Revenue 6.50 SAR 11.73 SAR 16.96 SAR 52

Asset-Based

NCAV (Graham) 9.46 SAR 14.33 SAR 17.91 SAR 54

Economic Profit

Residual Income 12.32 SAR 12.44 SAR 13.00 SAR 76

ROIC Compounder 7.11 SAR 7.95 SAR 8.64 SAR 72

Growth Earnings

Growth-Adj P/E 12.78 SAR 18.25 SAR 23.73 SAR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 36

How much profit the company makes from its sales and capital

Quality Growth 58

Are margins and returns getting better?

Cashflow 12

Do the profits arrive as real cash?

Financial strength 56

Debt, balance sheet and risk of trouble

Investment 96

Does it invest with discipline instead of growing at any price?

Low Volatility 88

How calm the share price moves, does not count

Momentum 22

Price trend of the last 3 to 12 months, does not count

Near the 52-week high 6

Distance to the 52-week high, does not count

New shares 54

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

−0.1%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.1%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.1%

Start year 2020 (pandemic)

Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+5.9%

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

−20.2%

Earnings growth per share plus dividend.

Earnings per share, growth per year−24.0%

Dividend (yield on the price)3.8%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 5%

4014 screens overvalued: fair value 52% below the price. Compare with Intuitive Surgical, Inc →

Compare Scientific and Medical Equipment House Company with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 187 stocks

Beats the industry median on 4/13 measures

Overall it trails its industry peers.

Valuation

Quality Score 50 · Below median

Fair Value upside −51.5% · Below median

Profitability

Return on equity (12 months) 5.0% · Below median

Return on assets 3.0% · Below median

Net margin (12 months) 3.5% · Below median

Operating margin (12 months) 7.9% · Below median

Growth and dividend

Revenue growth (quarter YoY) −22.1% · Bottom 25%

Dividend yield (12 months) 3.8% · Top 25%

Balance sheet

Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 28.4× · Pricier than median

P/B 1.54× · Cheaper than median

P/S (12 months) 0.99× · Cheapest 25%

EV/EBITDA 19.1× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 20

FUTURE (revenue growth)0 · sector 40

PAST (return on equity)20 · sector 28

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)77 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Solventum Corporation SOLV	$82.98	$133.48	+61%	vs 4014
EssilorLuxottica Société anonyme EL	€181.80	€196.22	+8%	vs 4014
Medline Inc MDLN	$33.69	$29.06	−14%	vs 4014
Intuitive Surgical, Inc ISRG	$445.88	$353.90	−21%	vs 4014
Alcon Inc ALC	$69.42	$40.13	−42%	vs 4014
Becton, Dickinson and Company BDX	$196.39	$104.73	−47%	vs 4014
Straumann Holding STMN	CHF 97.66	CHF 45.50	−53%	vs 4014
West Pharmaceutical Services, Inc WST	$398.29	$137.81	−65%	vs 4014
Sartorius Stedim Biotech S.A DIM	€221.80	€54.82	−75%	vs 4014
Sartorius Aktiengesellschaft SRT	€227.00	€42.50	−81%	vs 4014

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Scientific and Medical Equipment House Company · Fair Value
12.68 SAR −52%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/4014" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Scientific and Medical Equipment House Company · Fair Value</span><br><b style="font-size:20px">12.68 SAR</b> <span style="color:var(--red);font-weight:700;font-size:14px">−52%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Scientific and Medical Equipment House Company Fair Value". https://www.fairvalue-calculator.com/stock/4014

Frequently asked questions

Is Scientific and Medical Equipment House Company (4014) overvalued or undervalued?

As of Oct 27, 2026, our model estimates a fair value of 12.68 SAR versus a price of 26.16 SAR, about −52% upside (overvalued).

What is the fair value of 4014?

Our model-based fair value for Scientific and Medical Equipment House Company is 12.68 SAR (as of Oct 27, 2026), built from audited fundamentals. The current price: 26.16 SAR.

What is the quality score of 4014?

Scientific and Medical Equipment House Company has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Scientific and Medical Equipment House Company (4014)?

Our model-based price target is the fair value of 12.68 SAR (as of Oct 27, 2026) from 17 valuation models. Cautious scenario 9.46 SAR, optimistic scenario 16.88 SAR. It is a calculation from audited fundamentals, not an analyst target.

What is the Scientific and Medical Equipment House Company stock forecast for 2026?

Our models put fair value at 12.68 SAR, about −52% upside versus a price of 26.16 SAR (overvalued). Cautious scenario 9.46 SAR, optimistic scenario 16.88 SAR. The calculation is refreshed regularly with new filings.

What is the revenue of Scientific and Medical Equipment House Company (4014)?

Scientific and Medical Equipment House Company reported trailing-twelve-month revenue of about 786M SAR (latest available figure, as of Oct 27, 2026).

Does Scientific and Medical Equipment House Company pay a dividend?

Scientific and Medical Equipment House Company currently shows a dividend yield of 3.85% relative to its recent price (as of Oct 27, 2026).

What is the intrinsic value of Scientific and Medical Equipment House Company (4014)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Scientific and Medical Equipment House Company it is 12.68 SAR per share (as of Oct 27, 2026), against a price of 26.16 SAR. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).

Is Scientific and Medical Equipment House Company stock overvalued or undervalued in 2026?

As of Oct 27, 2026, 4014 trades above its calculated fair value: price 26.16 SAR, fair value 12.68 SAR, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 4014?

No. The price is what the market pays today (26.16 SAR); the fair value is what the company's own numbers justify (12.68 SAR). For Scientific and Medical Equipment House Company the two are 13.48 SAR per share apart. That gap is exactly why we show both numbers side by side.

How much is Scientific and Medical Equipment House Company worth?

The market values Scientific and Medical Equipment House Company at about 782M SAR (market capitalisation, as of Oct 27, 2026). Per share that is 26.16 SAR; our models calculate a fair value of 12.68 SAR per share.

What do the bullish and bearish scenarios say about 4014?

Our models span a range for Scientific and Medical Equipment House Company: cautious scenario 9.46 SAR, base 12.68 SAR, optimistic 16.88 SAR per share (as of Oct 27, 2026, price 26.16 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 4014?

Scientific and Medical Equipment House Company trades at a price-to-earnings ratio of 28.4 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 12.68 SAR is built from several models across several years. Other multiples: P/B 1.5, P/S 1.0, EV/EBITDA 19.1.

How solid is the balance sheet of Scientific and Medical Equipment House Company (4014)?

Balance-sheet figures for Scientific and Medical Equipment House Company (as of Oct 27, 2026): return on equity 5.0%, debt of 0.01 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.

How far is 4014 from its 52-week high?

Scientific and Medical Equipment House Company trades at 26.16 SAR, about 31% below its 52-week high of 37.93 SAR and 7% above the low of 24.47 SAR (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 12.68 SAR is for.

Which stocks are comparable to Scientific and Medical Equipment House Company?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Scientific and Medical Equipment House Company stock attractive at the current price?

The data as of Oct 27, 2026: price 26.16 SAR, calculated fair value 12.68 SAR (−52%), Quality Score 50/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 4014 calculated?

We run Scientific and Medical Equipment House Company through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 12.68 SAR, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.4 % above its aggregate fair value. Scientific and Medical Equipment House Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Scientific and Medical Equipment House Company (4014)?

The closing price on Oct 28, 2026 was 26.16 SAR. Our model-based fair value is 12.68 SAR, about −52% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Scientific and Medical Equipment House Company right now?

The price sits above even our optimistic bull case (16.88 SAR). The favourable scenario is already priced in. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Scientific and Medical Equipment House Company

How large is the market capitalisation of Scientific and Medical Equipment House Company (4014)?

The market capitalisation of Scientific and Medical Equipment House Company is 782M SAR (≈ $208M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Scientific and Medical Equipment House Company (4014)?

The price-to-sales ratio of Scientific and Medical Equipment House Company is 0.99 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Scientific and Medical Equipment House Company (4014)?

Earnings per share at Scientific and Medical Equipment House Company are 0.9200 SAR (price ÷ EPS = P/E 28.4). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Scientific and Medical Equipment House Company (4014)?

The dividend yield of Scientific and Medical Equipment House Company is 3.8% (payout 109%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Scientific and Medical Equipment House Company (4014)?

The net margin of Scientific and Medical Equipment House Company is 3.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Scientific and Medical Equipment House Company (4014)?

The return on equity (ROE) of Scientific and Medical Equipment House Company is 5.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Scientific and Medical Equipment House Company (4014)?

On an EBIT basis the return on assets of Scientific and Medical Equipment House Company is 6.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Scientific and Medical Equipment House Company (4014)?

The operating margin of Scientific and Medical Equipment House Company is 7.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Scientific and Medical Equipment House Company (4014)?

Revenue at Scientific and Medical Equipment House Company is growing −22.1% versus a year earlier (3y avg +7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Scientific and Medical Equipment House Company (4014)?

Earnings per share at Scientific and Medical Equipment House Company are growing −12.0% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Scientific and Medical Equipment House Company (4014) generate?

The free cash flow of Scientific and Medical Equipment House Company is −12.8M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Scientific and Medical Equipment House Company (4014) carry?

The net debt of Scientific and Medical Equipment House Company is 171M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Scientific and Medical Equipment House Company in the live analysis

One click puts Scientific and Medical Equipment House Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.